Pfizer received FDA approval May 6 for Vyndaqel, which treats a rare and fatal heart disease. The drug will launch with a list price of $225,000 per year in the U.S., according to Reuters.
Vyndaqel, the brand name for the medicine known as tafamidis, is approved to treat transthyretin amyloid cardiomyopathy. Pfizer said the disease affects about 100,000 people in the U.S., the majority of whom are undiagnosed. About 2,000 to 5,000 patients are currently diagnosed with the heart disease worldwide.
Pfizer told Reuters it is confident that insurers will reimburse the $225,000 price.
Outside the U.S. the drug sells for about $100,000 a year.
Analysts expect sales of the drug to exceed $1 billion by 2024.
Read the full report here.